Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
Clinical trial NCT05636436 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05636436
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-07
- Primary completion
- 2024-12-30
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.